Related Experiment Video
Updated: May 24, 2026
08:27
Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease
Published on: September 20, 2018
Combined Upadacitinib and Vedolizumab as 8-Week Induction Therapy for Moderate-to-Severe Ulcerative Colitis: A
Jiayin Yao1, Hongzhen Wu1, Luying Wu1
1Department of Gastroenterology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China; Guangdong Provincial Clinical Research Center for Digestive Diseases, Guangzhou, Guangdong, China.
Summary
Combination therapy with upadacitinib and vedolizumab significantly improved endoscopic remission in ulcerative colitis patients compared to vedolizumab alone. This short-term induction strategy offers a promising new approach for moderate-to-severe disease.
Area of Science:
- Gastroenterology
- Immunology
- Pharmacology
Background:
- Current ulcerative colitis therapies have an efficacy ceiling, with limited endoscopic remission rates.
- Advanced therapies for ulcerative colitis (UC) often fail to achieve deep remission.
- Novel therapeutic strategies are needed to overcome the limitations of existing UC treatments.
Purpose of the Study:
- To evaluate if combination therapy (upadacitinib and vedolizumab) is superior to vedolizumab monotherapy for ulcerative colitis.
- To assess the efficacy of an 8-week induction with upadacitinib and vedolizumab followed by vedolizumab monotherapy.
- To determine if combination therapy can achieve higher endoscopic remission rates in moderate-to-severe UC.
Main Methods:
- A prospective, multicenter, randomized, open-label superiority trial involving adults with moderate-to-severe ulcerative colitis.
- Patients were randomized 1:2 to receive either combination therapy (vedolizumab + upadacitinib for 8 weeks) or vedolizumab monotherapy.
- The primary endpoint was endoscopic remission (Mayo endoscopic subscore of 0) at week 8, assessed by blinded central readers.
Main Results:
- Combination therapy achieved significantly higher endoscopic remission rates at week 8 (37.5% vs. 15.1%, P = .010).
- Clinical remission (65.0% vs. 35.6%, P = .002) and histologic-endoscopic mucosal improvement (40.0% vs. 13.7%, P = .004) were also significantly higher with combination therapy.
- Adverse event rates were comparable between the groups, with no serious adverse events reported.
Conclusions:
- Short-term induction with combined upadacitinib and vedolizumab is superior to vedolizumab monotherapy for achieving endoscopic and clinical remission in moderate-to-severe ulcerative colitis.
- This study provides the first randomized evidence for a short-term combination biologic and small-molecule induction strategy in UC.
- Findings suggest a potential new approach for managing ulcerative colitis, though caution is advised due to trial design and early termination.
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...